14899-36-6

• 常用中文名：地塞米松棕榈酸酯
• 常用英文名：Dexamethasone Palmitate
• CAS号：14899-36-6
• 分子式：C₃₈H₅₉FO₆
• 分子量：630.870
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 糖皮质激素受体
• 发布时间：2018-09-07 18:00:30
• 更新时间：2026-07-16 20:21:15
• Dexamethasone palmitate (DXP) 是 Dexamethasone 的前药。Dexamethasone 是一种糖皮质激素受体 (glucocorticoid receptor) 激动剂。Dexamethasone palmitate (DXP) 对糖皮质激素受体的亲和力比 Dexamethasone 低 47 倍。具有抗炎活性。

名称

• 中文名: 地塞米松棕榈酸酯
• 英文名: Dexamethasone 21-Palmitate
• 中文别名: 地塞米松杂质20 CRS(地塞米松棕榈酸酯 CRS); 地塞米松棕榈酸酯,10 MM DMSO 溶液; 棕榈酸地塞米松; 地塞米松棕榈酸; 地塞米松21-棕榈酸酯; 地塞米松21-棕榈酸; 棕榈酸[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-氟-11,17-二羟基-10,13,16-三甲基-3-氧代-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊并[A]菲-17-基]-2-氧代乙基]酯; 罗恩 地塞米松棕榈酸酯 R115190; 地塞米松杂质24; 棕榈酸酯地塞米松; 地塞米松棕榈酸地; 地塞米松杂质23; 地塞米松杂质20(地塞米松棕榈酸酯)
• 英文别名: Dexamethasone palmitate (jan); Lipotalon; dexamethasone palmitate; lipophilic,prodrug,RAW 264.7,VEGF,Dexamethasone palmitate,Dexamethasone,Inhibitor,inflammation,inhibit,cytokine; dexapalmitate; Limethason (tn); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxohexadecyl)oxy]-, (11β,16α); Palmitic acid, 21-ester with 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione (8CI); DEXAMETHASOME PALMITATE; Limethason; Dexamethasone Palmitate Corticosteroid Raw Powder; 9-Fluoro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione 21-Palmitate; Dexamethasone-21-palmitate; Hexadecanoic acid, (11β,16α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl ester; 21-(Palmitoyloxy)-9α-fluoro-11β,17α-dihydroxy-16α-methyl-1,4-pregnadiene-3,20-dione; (11β,16α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl hexadecanoate; 2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl Palmitate; Dexamethasone Impurity 20 CRS（Dexamethasone Palmitate CRS）; 21-Dehydrodexamethasone Dihydrate; (11β,16α)-9-Fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl palmitate; Pregna-1,4-diene-3,20-dione, 9-fluoro-11β,17,21-trihydroxy-16α-methyl-, 21-palmitate (6CI, 8CI); (11β,16α)-9-Fluoro-11,17-dihydroxy-16-Methyl-21-[(1-oxohexadecyl)oxy]pregna-1,4-diene-3,20-dione; Dexamethasone palmitate (JAN); Dexamethasone palmitate; D01615; Dexamethasone Impurity 21（Dexamethasone Palmitate）; Dexamethasone palmitate (DXP); DXM-21-palmitate; Dexamethasone palmitate, 10 mM in DMSO; 9-Fluoro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione 21-palmitate; Dexamethasone Impurity 20（Dexamethasone Palmitate）; Limethasone

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 710.1±60.0 °C at 760 mmHg
• 熔点: 60-65ºC
• 分子式: C₃₈H₅₉FO₆
• 分子量: 630.870
• 闪点: 383.2±32.9 °C
• 精确质量: 630.429565
• PSA: 100.90000
• LogP: 10.40
• 蒸汽压: 0.0±5.1 mmHg at 25°C
• 折射率: 1.537
• 储存条件: -20°C，惰性气体保护

生物活性

• 描述: Dexamethasone palmitate (DXP) 是 Dexamethasone 的前药。Dexamethasone 是一种糖皮质激素受体 (glucocorticoid receptor) 激动剂。Dexamethasone palmitate (DXP) 对糖皮质激素受体的亲和力比 Dexamethasone 低 47 倍。具有抗炎活性。
• 相关类别:
  研究领域 >> 炎症/免疫
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体
• 参考文献:

  [1]. Lorscheider M, et al. Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. J Control Release. 2019 Feb 28;296:179-189.

  [2]. Daull P, et al. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther. 2013 Mar;29(2):258-69.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : TU4061000 CHEMICAL NAME : Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-, 21-palmitate CAS REGISTRY NUMBER : 14899-36-6 LAST UPDATED : 199612 DATA ITEMS CITED : 13 MOLECULAR FORMULA : C38-H59-F-O6 MOLECULAR WEIGHT : 630.97 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 315 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 90 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 88 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 510 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 120 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 550 ug/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4521,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 250 ug/kg SEX/DURATION : multigenerations TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4539,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 55 ug/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4521,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 25 ug/kg SEX/DURATION : multigenerations TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4539,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 325 ug/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4555,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 65 ug/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4555,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 325 ug/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,4555,1985